Clinical Trial Update: Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS

View source ↗

Summary

A completed real-world evidence study in Korea assessed the safety and efficacy of osimertinib for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Status: COMPLETED